Loading patent…
AssigneeMolecular Partners AG
InventorsNina RESCHKE, Sebastian GRIMM, Christian REICHEN, Bernd SCHLERETH, Victor LEVITSKY, Matteo BIANCHI
Estimating the term…
The present invention relates to recombinant multi-specific proteins comprising binding agents with binding specificity for different targets, such as, e.g. CD3, CD33, CD123 and CD70. In addition, the invention relates to nucleic acids encoding such multi-specific proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such binding proteins, nucleic acids or pharmaceutical compositions in methods for treating or diagnosing diseases, such as cancer, e.g. acute myeloid leukaemia (AML), in a mammal, including a human.
A recombinant protein comprising (1) a first binding agent that specifically binds to a protein expressed on the surface of an immune cell, and (2) at least two binding agents that specifically bind to a tumor-associated antigen, wherein said two binding agents specifically bind to different tumor-associated antigens.
A recombinant protein comprising a polypeptide having the amino acid sequence of SEQ ID NO:
Dependencies are inferred from the claim text.